Friederike Kortüm

Dr. Friederike Kortüm

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2022 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
FRFelix F Reichel
Felix F Reichel
ISImmanuel Seitz
Immanuel Seitz
FWFabian Wozar
Fabian Wozar
SDSpyridon Dimopoulos
Spyridon Dimopoulos
RJRonja Jung
Ronja Jung
MFM. Dominik Fischer
M. Dominik Fischer
Background/aims: Voretigene neparvovec (VN) is the first and only subretinal gene therapy approved by the Food and Drug Administration and European Medicines Agency. Real-world application has started in 2018 in patients with vision impairment due to biallelic retinal pigment epithelium (RPE)65mutation-associated inherited retinal degenerations. Herein, we evaluated the development of retinal atrophy within in a single-centre patient cohort treated with VN.Methods: 13 eyes of eight patients treated with VN were retrospectively analysed for areas of retinal atrophy over a period of 6–24 months following surgery. Ultrawide field images were used to measure the area of atrophy. Fundus autofluorescence imaging is presented as an instrument for early detection of signs of retinal atrophy in these patients.Results: Atrophic changes beyond the retinotomy site were observed in all eyes. Areas of atrophy developed within the area of detachment (bleb) in all eight patients and outside the bleb in three patients. Changes in autofluorescence preceded the development of retinal atrophy and were already evident 2 weeks after surgery in the majority of patients. The areas of atrophy increase with time and progression continued over year 1. Functional outcomes remained stable (VA, FST, visual field).Conclusion: Subretinal injection of VN can lead to RPE atrophy with consequent photoreceptor loss in and outside of the bleb area. Fundus autofluorescence is an important tool to monitor atrophic changes in patients after gene therapy. Interestingly, while areas of atrophy also included central areas, the functional benefits of the treatment did not appear to be affected and remained stable.

21 February 2023 in Ophthalmology
Verified
Journal Article
Closed access
KSKatarina Stingl
Katarina Stingl
KSKrunoslav T. Stingl
Krunoslav T. Stingl
HSHillary Schwartz
Hillary Schwartz
MRMark W. Reid
Mark W. Reid
MKMelanie Kempf
Melanie Kempf
ANAaron Nagiel
Aaron Nagiel

9 September 2022 in Progress in Retinal and Eye Research
Verified
Journal Article
Open access
KSKrunoslav T. Stingl
Krunoslav T. Stingl
MKMelanie Kempf
Melanie Kempf
Ronja JungRonja Jung
Ronja Jung
FKFriederike Kortüm
Friederike Kortüm
GRGiulia Righetti
Giulia Righetti
KSKatarina Stingl
Katarina Stingl
Retinal gene supplementation therapy such as the first approved one, voretigene neparvovec, delivers a functioning copy of the missing gene enabling the protein transcription in retinal cells and restore visual functions. After gene supplementation for the genetic defect, a complex network of functional regeneration is the consequence, whereas the extent is very individualized. Diagnostic and functional testings that have been used routinely by ophthalmologists so far to define the correct diagnosis, cannot be applied in the new context of defining small, sometimes subtle changes in visual functions. New view on retinal diagnostics is needed to understand this processes that define safety and efficacy of the treatment. Not only does vision have many aspects that must be addressed by specific evaluations and imaging techniques, but objective readouts of local retinal function for rods and cones separately have been an unmet need until recently. A reliable test-retest variability is necessary in rare diseases such as inherited retinal dystrophies, because statistics are often not applicable due to a low number of participants. Methods for a reliable individual evaluation of the therapy success are needed. In this manuscript we present an elaboration on retinal diagnostics combining psychophysics (eg. full-field stimulus threshold or dark adapted perimetry) as well as objective measures for local retinal function (eg. photopic and scotopic chromatic pupil campimetry) and retinal imaging for a meaningful workflow to apply in evaluation of the individual success in patients receiving gene therapy for photoreceptor diseases.

20 January 2021 in British Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
KSKrunoslav T. Stingl
Krunoslav T. Stingl
MKMelanie Kempf
Melanie Kempf
KBKarl U Bartz-Schmidt
Karl U Bartz-Schmidt
SDSpyridon Dimopoulos
Spyridon Dimopoulos
FRFelix Reichel
Felix Reichel
KSKatarina Stingl
Katarina Stingl
Background: Voretigene neparvovec is a gene therapeutic agent for treatment of retinal dystrophies caused by bi-allelic RPE65 mutations. In this study, we report on a novel and objective evaluation of a retinotopic photoreceptor rescue.Methods: Seven eyes of five patients (14, 21, 23, 24, 36 years, 1 male, 4 females) with bi-allelic RPE65 mutations have been treated with voretigene neparvovec. The clinical examinations included visual acuity testing, dark-adapted full-field stimulus threshold (FST), dark-adapted chromatic perimeter (DAC) with a 30-degree grid, and a 30 degrees grid scotopic and photopic chromatic pupil campimetry (CPC). All evaluations and spectral domain optical coherence tomography were performed at baseline, 1 month and 3 months.Results: All except the oldest patient had a measurable improvement of the rod function assessed via FST, DAC or scotopic CPC at 1 month. The visual acuity improved slightly or remained stable in all eyes. A cone function improvement as measured by photopic CPC was observed in three eyes. The gain of the dark-adapted threshold with blue FST and the DAC stimuli (cyan) average correlated strongly with age (R2>0.7). The pupil response improvement in the scotopic CPC correlated with the baseline local retinal volume (R2=0.5).Conclusions: The presented protocols allow evaluating the individual spatial and temporal effects of gene therapy effects. Additionally, we explored parameters that correlated with the success of the therapy. CPC and DAC present new and fast ways to assess functional changes in retinotopic maps of rod and cone function, measuring complementary aspects of retinal function.

21 July 2021 in Acta Ophthalmologica
Verified
Journal Article
Open access
FKFriederike Kortüm
Friederike Kortüm
MKMelanie Kempf
Melanie Kempf
RJRonja Jung
Ronja Jung
SKSusanne Kohl
Susanne Kohl
SOSaskia Ott
Saskia Ott
KSKatarina Stingl
Katarina Stingl
Purpose: Leber congenital amaurosis type 2 (LCA2) and early‐onset severe retinal dystrophy (EOSRD) are linked to visual impairment with nyctalopia and visual acuity reduction in early childhood. In 2017, the first gene therapy voretigene neparvovec (Luxturna™) for patients with LCA and EOSRD cause by bi‐allelic mutations in the RPE65 gene has been approved. Here we report on an example of short‐term change in the foveal morphology after functionally successful gene therapy with voretigene neparvovec in a 15‐year old patient.Methods: The clinical examinations included best corrected visual acuity (BCVA), spectral domain optical coherence tomography (OCT) and adaptive optics retinal imaging.Results: During follow‐up over a period of 3 months after the treatment, an improvement of the central foveal morphology could be observed in OCT, with a clear demarcation of the external limiting membrane and changes in the photoreceptor mosaic on adaptive optics retinal imaging. These morphological rescue parameters correlated in part with the improvement in foveal‐mediated vision after the treatment and adaptive optics imaging. Although the visual acuity improved only slightly at month 3, objective central cone evaluation with chromatic pupil campimetry showed an increase in the central sensitivity. In daily life, the patient reported her visional experience after the treatment as ‘brighter’.Conclusion: Rapid changes in the correlates of photoreceptor morphology after successful gene therapy in patients with LCA/EORD can be quantifiable on individual level.

Verified
Journal Article
Open access
PDF file
FKFriederike Kortüm
Friederike Kortüm
SKSinja Kieninger
Sinja Kieninger
PMPascale Mazzola
Pascale Mazzola
SKSusanne Kohl
Susanne Kohl
BWBernd Wissinger
Bernd Wissinger
NWNicole Weisschuh
Nicole Weisschuh
We aimed to validate the effect of non-canonical splice site variants in the RPGR gene in five patients from four families diagnosed with retinitis pigmentosa. Four variants located in intron 2 (c.154 + 3_154 + 6del), intron 3 (c.247 + 5G>A), intron 7 (c.779-5T>G), and intron 13 (c.1573-12A>G), respectively, were analyzed by means of in vitro splice assays. Splicing analysis revealed different aberrant splicing events, including exon skipping and intronic nucleotide addition, which are predicted to lead either to an in-frame deletion affecting relevant protein domains or to a frameshift of the open reading frame. Our data expand the landscape of pathogenic variants in RPGR, thereby increasing the genetic diagnostic rate in retinitis pigmentosa and allowing patients harboring the analyzed variants to be enrolled in clinical trials.